Abstract: The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of one or more anti-cancer agents, including Erlotinib. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.

Abstract: Disclosed is the use of a combination of histone deacetylase inhibitors and kinase inhibitors with anti-EGFR activity.

Abstract: Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to EGFR inhibitors, and products and processes related thereto. In one embodiment, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.

Abstract: Disclosed are biomarkers, methods and assay kits for the identification of cancer patients who are predicted to benefit, or not to benefit, from the therapeutic administration of an epidermal growth factor receptor (EGFR) inhibitor. The biomarkers of the present invention include detection of EGFR and HER 2 gene amplification and polysomy, EGFR protein expression, EGFR mutations, phosphorylated Akt protein expression, and various combinations of such biomarkers, as well as the combination of these biomarkers with mutations in the tyrosine kinase domain of the EGFR gene. Increased EGFR gene copy number, increased HER2 gene copy number, increased EGFR, protein expression, activated AKT protein expression (phosphorylated AKT) and EGFR mutations are all associated with better outcome for cancer patients treated with EGFR inhibitors.

Abstract: The invention provides for water-dispersible microparticles comprising magnetic material and organic substance, such as a pharmaceutical or a pigment, that constitute in totality at least 50%, or preferably more that 70%, of the dry mass of the particle. The method of making such microparticles is also provided, comprising coating of the magnetic material in an aqueous colloid form with a layer of a polyelectrolyte, and combining the coated colloid with the organic substance having ionic charge opposite to that of the polyelectrolyte. When the organic substance is poorly soluble in water, the combining comprises dissolving of the substance in a water-miscible organic solvent, and combining said solution with the polyelectrolyte-coated magnetic colloid. The magnetic pharmaceutical microparticles are useful for magnetically-guided drug delivery, and/or for non-invasive monitoring of the drug distribution in the body. Magnetic microparticles comprising dyes and pigments are useful in magnetic inks.

Abstract: Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to gefitinib and other EGFR inhibitors, and products and processes related thereto. Specifically, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for the detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.

Abstract: The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of one or more anti-cancer agents, including Erlotinib. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.

Abstract: The invention provides bradykinin antagonists and pharmaceutically acceptable salts thereof having anti-cancer activity. These anti-cancer compounds are particularly useful for inhibiting the growth of lung and prostate cancers.

Abstract: The present invention provides compounds useful to inhibit tumor growth and to induce apoptosis. In general, the anti-cancer agents (ACA) are described by the formula: [ACA]n-X[Formula I] wherein X is a linker group having 2–5 functional groups or is absent, n=1, and ACA is selected from the group consisting of Formula II, Formula III, Formula IV, Formula V, and Formula VI, as described herein. Other compounds described herein are defined by the Formula VII, as described herein.

Abstract: The present invention provides compounds useful to inhibit tumor growth and to induce apoptosis.

Abstract: An adaptor for a hand-held flashlight is disclosed, the flashlight being of the type having an elongate handle defying a battery compartment. The adaptor comprises a fitting in the form of a cylindrical handle-receiving aperture for mounting the flashlight handle detachably in a friction fit A multi-directional connector joins the flashlight fitting to one of a number of interchangeable bases, which may be coupled detachably to a mounting plate. The mounting plate may be formed with strap mounting formations for carrying a headstrap or the like. Both the base-plate and the interchangeable bases may be formed with suction caps, plugs, keyed apertures or magnets for mounting them detachably to various fixtures. As a result, the hand-held flashlight may be readily adapted for hands-free use.

Abstract: The present invention provides compounds useful to inhibit tumor growth and to induce apoptosis. In general, the anti-cancer agents (ACA) are described by the formula: [ACA]n-X  [Formula I] wherein X is a linker group having 2-5 functional groups or is absent, n=1, and ACA is selected from the group consisting of Formula II, Formula III, Formula IV, Formula V, and Formula VI, as described herein. Other compounds described herein are defined by the Formula VII, as described herein.

Abstract: The present invention comprises a material and a method of its preparation. The material may be described as hydrophilic microparticles, comprising a cluster of organic substance with a layer of polyelectrolyte on its surface. The present invention establishes an improved method for preparing aqueous colloidal dispersions of water-insoluble organic substances using polyionic hydrophilic polymers by which the stability of the suspension is maintained after removal of the stabilizing and/or solubilizing medium of the drug. This improved method can be utilized to formulate a variety of water-insoluble organic substances.

Abstract: The present invention relates generally to a non-toxic lipid conjugated with a cationic amino acid containing a guanidino group. Specifically, the naturally-occuring lipid DOPE is combined with the naturally-occurring amino acid Arginine. These compounds are useful for encapsulating and delivering pharmaceuticals and poly and oligonucleotides. These compound improve over current compounds, because they are composed of non-toxic and, in the case of Arg-DOPE, natural components, and therefore result in minimal unwanted side effects. Methods of use of the cationic lipids are also claimed.

Abstract: The invention relates to a file stiffener for stiffening a file of the type having a pair of opposed covers hinged to and spaced apart from one another by a spine, in particular for ring binder and lever arch-type files. The file stiffener comprises at least one rigidifying spacer element, and mounting means for mounting the spacer element between the opposed covers, the spacer element being dimensioned to hold the covers apart in a rigid parallel configuration.

Abstract: Superparamagnetic particles are provided for medical applications including hyperthermia techniques, localized heating and tissue-specific release of therapeutic agents, and magnetic resonance imaging contrast enhancement, comprising superparamagnetic iron oxide and a polymer such as dextran at a ratio of about 0.5 to 0.1 w/w of polymer to iron. The particles display at least one of the following magnetic properties: (a) specific power absorption rate greater than 300 w/g Fe; (b) initial magnetic susceptibility greater than 0.7 EMU/g Fe/Gauss; and (c) magnetic moment greater than 10.sup.-15 erg/Gauss.